# Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

> **NCT01739660** · PHASE1 · COMPLETED · sponsor: **Savient Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Chronic Kidney Disease Stage 5

## Interventions

- **DRUG:** Pegloticase

## Key facts

- **NCT ID:** NCT01739660
- **Lead sponsor:** Savient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739660, "Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01739660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*